Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

NCT05656131 · clinicaltrials.gov ↗

PHASE2

Phase

SUSPENDED

Status

80

Enrollment

OTHER

Sponsor class

Stopped Suspended

Conditions

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer

Interventions

DRUG: Fluzoparib
DRUG: Fluzoparib+Camrelizumab

Sponsor

wang shusen